Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
This article was originally published in The Pink Sheet Daily
Launching a competing epinephrine product has proved challenging, which is good news for Mylan. Teva disclosed the receipt of a complete response letter to its ANDA, just months after Sanofi voluntarily recalled Auvi-Q due to inaccurate dose delivery.
Register for our free email digests: